Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (81-90 of 250) with videos related to

Pageof 25
Sort By:
Archives of Pathology & Laboratory Medicine|October 3, 2022
Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine TumorsJisup Kim, Dong-Hoon Yang, HaeSung Jung, et al.
Investigational New Drugs|December 8, 2018
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinomaChanghoon Yoo, Joong-Won Park, Yoon Jun Kim, et al.
Annals of Surgical Oncology|March 21, 2015
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with ImatinibChanghoon Yoo, Young Wha Koh, Young Soo Park, et al.
Plos One|June 16, 2021
Radiation therapy for recurrent extrahepatic bile duct cancerMinji Koh, Jin-Hong Park, Changhoon Yoo, et al.
Investigational New Drugs|May 29, 2013
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancerChanghoon Yoo, Min-Hee Ryu, Young-Soon Na, et al.
Journal of Breast Cancer|April 10, 2018
<i>FcrR3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based TreatmentHeejung Chae, Changhoon Yoo, Jung-A Yoon, et al.
Targeted Oncology|October 3, 2024
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-PacificSejin Kim, Suat Ying Lee, Jaekyung Cheon, et al.
International Journal of Hematology|January 30, 2013
Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphomaChanghoon Yoo, Dok Hyun Yoon, Jeong Eun Kim, et al.
Liver Cancer|August 20, 2025
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus BevacizumabJaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, et al.
The Lancet. Oncology|October 22, 2013
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trialYoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, et al.
Pageof 25

Showing results (81-90 of 250) with videos related to

Sort By:
Pageof 25
Archives of Pathology & Laboratory Medicine|October 3, 2022
Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine TumorsJisup Kim, Dong-Hoon Yang, HaeSung Jung, et al.
Investigational New Drugs|December 8, 2018
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinomaChanghoon Yoo, Joong-Won Park, Yoon Jun Kim, et al.
Annals of Surgical Oncology|March 21, 2015
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with ImatinibChanghoon Yoo, Young Wha Koh, Young Soo Park, et al.
Plos One|June 16, 2021
Radiation therapy for recurrent extrahepatic bile duct cancerMinji Koh, Jin-Hong Park, Changhoon Yoo, et al.
Investigational New Drugs|May 29, 2013
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancerChanghoon Yoo, Min-Hee Ryu, Young-Soon Na, et al.
Journal of Breast Cancer|April 10, 2018
<i>FcrR3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based TreatmentHeejung Chae, Changhoon Yoo, Jung-A Yoon, et al.
Targeted Oncology|October 3, 2024
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-PacificSejin Kim, Suat Ying Lee, Jaekyung Cheon, et al.
International Journal of Hematology|January 30, 2013
Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphomaChanghoon Yoo, Dok Hyun Yoon, Jeong Eun Kim, et al.
Liver Cancer|August 20, 2025
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus BevacizumabJaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, et al.
The Lancet. Oncology|October 22, 2013
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trialYoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, et al.
Pageof 25